An alternative therapeutic approach that has been extensively studied over the last 25 years is the use of the CFTR cDNA, delivered directly to the lung, to complement the genetic defect in CFTR. This approach could potentially be curative, at least for CF lung disease, in a manner that is independent of the disease-causing variants. This evidence concerns the gene CFTR and cystic fibrosis.